Despite detailed evaluation of disease-associated prognostic factors, little is known about the impact of overweight in autograft programs for non-Hodgkin's lymphoma (NHL) patients. In order to address this issue, 121 NHL patients were retrospectively evaluated. They had been upfront (92 patients) or in relapse (29 patients) and received high-dose sequential (HDS) chemotherapy including peripheral blood progenitor cell (PBPC) autograft. Body mass index (BMI) was calculated as weight in kilograms divided by the square of the height in meters; overweight was defined as BMI у28. Univariate and multivariate analyses were used to determine the prognostic implication of overweight and other known prognostic indicators on overall (OS) and event-free (EFS) survival for the entire group and overweight and non-overweight (reference) subgroups. With a median follow-up of 3 years, the estimated 5-year OS and EFS for the entire group were 58% and 49%, respectively. Twenty-eight patients (23%) had BMI у28. Their median OS and EFS were 2.2 and 1.4 years, respectively, whereas median OS and EFS for the reference group have not been reached, with a 5-year projection of 65 and 55%, respectively (P Ͻ 0.002). On multivariate analysis, the risk of death among overweight patients was 2.9 (CI, 1.3-6.2) times that of the reference group; using EFS as the end point, a similar association between overweight and survival was observed. In conclusion, in high-risk NHL patients undergoing intensive chemotherapy and PBPC autografting overweight is associated with a poorer outcome. Bone Marrow Transplantation (2000) 26, 1185-1191.
the best therapeutic option available for relapsed intermediate-high-grade NHL. 1 Some evidence has been produced that this approach may also be superior to standard chemotherapy in low-grade lymphomas, in particular in follicular subtypes. 2, 3 More recently, due to the clinical use of hemopoietic growth factors and peripheral blood progenitor cells (PBPC), high-dose strategies followed by a final submyeloablative consolidation have become much more widely used. [4] [5] [6] Several studies have shown that this approach can also be successfully employed in different types of lymphoma at disease onset. [7] [8] [9] [10] [11] [12] [13] [14] As a rule, high-dose treatments are now employed in patients with adverse prognostic factors. [15] [16] [17] According to common prognostic parameters, patients enrolled in autograft programs are a relatively homogeneous group. Hence, new studies are needed, aimed at evaluating other variables, in order to identify which patients are likely to have less chance of success if enrolled in such intensive trials. With this in mind, we investigated the role of body mass. Previous reports have documented the adverse prognostic impact of obesity for patients receiving standard-dose chemotherapy for breast cancer. 18, 19 More recently, two studies in patients undergoing allogeneic bone marrow transplantation for different hematologic diseases have shown a worse clinical outcome in patients with increased body mass. 20, 21 However, there are presently no data concerning the impact of overweight on the clinical outcome of lymphoma patients undergoing therapeutic programs based on autografting.
In an attempt to identify the prognostic value of overweight, we focused our analysis on patients with NHL undergoing a high-dose sequential chemotherapy program including a final autograft performed with mobilized peripheral blood progenitor cells. A retrospective analysis showed that high body mass is associated with poor outcome. Multivariate analysis has confirmed that overweight is an independent prognostic factor in the high-dose approach with autograft. These data support the hypothesis that overweight is a prognostic factor that should be considered when an NHL patient is enrolled in an intensive program including autograft with peripheral blood progenitor cells.
Patients and methods

Patient characteristics and study design
A retrospective analysis on the association between overweight and long-term outcome was carried out by collecting data from advanced-stage, NHL patients treated at the University Division of Hematology of Turin, Italy between 1990 and 1997. The patient sample selected for this analysis included 121 patients eligible and consenting to undergo a treatment based on two high-dose sequential (HDS) chemotherapy protocols, including peripheral blood progenitor cell (PBPC) autograft. All enrolled patients had histologically confirmed NHL. They received an HDS program either at disease onset, if they presented with advanced-stage and poor prognostic features, or at disease relapse. Eligibility criteria included normal heart, renal and liver function, as well as negative tests for HIV, HBsAg and HCV.
Quatelet's index, defined as weight in kg divided by the square of the height in meters, was used to calculate body mass index (BMI). This formula is the most widely employed weight measure adjusted for height. 22, 23 Patients were divided into two main groups according to their BMI, assuming BMI value у28 as cut-off to identify overweight patients; the remaining patients with BMI Ͻ28 represented the reference group. Previous reports have proposed a 28 BMI value as threshold level to define an overweight state. 23, 24 Additional analyses (not presented in detail) explored the use of different cut-offs, including three categories with BMI Ͻ26, 24, 22. Most patients presented with advanced-stage disease, high serum LDH levels or symptomatic disease. Prognostic presentation was also assessed using the age-adjusted International Prognostic Index (IPI) score. 16 The majority of patients were assigned the highrisk 2-3 score. Main clinical characteristics of patients in the two groups are summarized in Table 1 . No significant differences were seen between the two groups in the distribution of main clinical features.
Treatment schedules
All patients received either the original HDS chemotherapy regimen or its further intensified version (i-HDS), specifically designed for patients presenting with bone marrow involvement. 4, 14 The original HDS regimen includes the sequential administration of: (1) 2 , at approximately day 23; (4) submyeloablative treatment with PBPC autograft approximately between day 48 and 52. The main modification of i-HDS consisted of an intensive debulkying prior to the HD phase with two complete APO courses given at full dose; patients not reaching CR after APO received two additional DHAP courses. In the HD phase, the CY/VP16 sequence was inverted, in order to schedule PBPC harvest at the end of the HD scheme. In addition, a chemotherapy-free interval of 30 days was included prior to HD CY in order to allow adequate marrow repopulation. 14 In the chemotherapy-free interval, a total of three HD dexamethasone courses (dexamethasone at 40 mg/day for 4 consecutive days) were administered every 10 days. G-CSF (filgrastim) was given at 5 g/kg/day following CY, VP16, and after autograft, until myelopoietic recovery. The combined administration of HD mitoxantrone and HD L-PAM was used as conditioning in the great majority of patients. 25 The BEAM schedule was used as conditioning in five patients. 26 In any event the drug dose was calculated on actual patient weight; a drug dose reduction based on pharmacologic weight was only employed in six out of the nine massively obese patients (with BMI у32). Radiotherapy was given to bulky sites approximately 2 months after autograft.
Statistical analysis
The proportion of patients with a given characteristic was compared in the two BMI groups; statistical significance of the difference was tested with the chi-square test. Differences in severity and duration of post-chemotherapy hematologic and extrahematologic complications between overweight and reference groups were evaluated either by the chi-square test or by the non-parametric, two-sided MannWhitney test. A P value Ͻ0.05 was assumed to denote statistical significance. Survival duration was measured from treatment start to the day of death or last follow-up evaluation. Event-free survival duration was calculated from treatment start up to the first adverse event, ie failure to reach complete remission (CR), relapse, treatment-related or disease-related deaths or the date the patient was last known to be in remission. The actuarial duration of overall survival (OS) and event-free survival (EFS) were plotted as curves according to the Kaplan and Meier product-limit method. 27 Differences between the curves were appraised by the log-rank method. Regression modelling techniques were used to evaluate the association of survival with body size and prognostic factors (Cox proportional hazard model). 28 The following variables were included in the analysis: age (Ͻ vs у45 years), sex, age-adjusted IPI score (0-1 vs 2-3), bone marrow infiltration, diagnosis vs relapse, histology (low grade vs mantle-cell vs intermediate/high grade), BMI (Ͻ vs у28).
Results
Distribution of patients according to BMI
Among 121 patients entering the study protocols, 93 (77%) had BMI Ͻ28 and 28 (23%) had BMI у28. Five (4%) patients had BMI Ͻ19, 23 (19%) had BMI between 19 and 21.9, 38 (31%) had BMI between 22 and 24.9, 27 (22%) had BMI between 25 and 27.9, 19 (16%) had BMI between 28 and 31.9 and 9 (7%) had BMI у32.
Overall toxicity and treatment feasibility
Two patients in the reference group and one in the overweight group died early in the scheduled treatment due to septic shock (two patients) and cerebral hemorrhage. There were two additional toxic deaths, one in the overweight group due to cardiac arrest immediately prior to the final autograft phase and one in the reference group due to persistent pancytopenia following extensive abdominal radiotherapy after autograft. Thus five (4%) out of 121 patients died of treatment-related causes. All patients experienced relatively short periods of pancytopenia and fever following HD cytotoxic drug administration and autograft, according to previously reported results in the HDS programs. 6, 8, 14 Oral mucositis was the most frequent severe extrahematologic complication, occurring in any case after autograft. There were no major differences between BMI groups in the overall HDS toxicity, with a slightly better tolerance in BMI у28 compared to the reference group, in terms of reduced transfusion requirement and a lower incidence and duration of fever; however, the differences never reached statistical significance.
Besides the five toxic deaths, 17 patients (12 in the reference group and five in the overweight group) were not able to complete the final autograft phase. Reasons for not proceeding to autograft were: disease progression (nine patients), refusal of autograft (two patients), hepatic toxicity (one patient) in the reference group; disease progression (three patients), hepatic toxicity (one patient), discovery of a second tumor (one patient) in the overweight group.
Overall survival and event-free survival
With a median follow-up of 3 years, the estimated 5-year OS and EFS for the entire patient group were 58% and 49%, respectively; both values remained unchanged at 9 years. Statistically significant differences in both OS and EFS were clear when patients were classified according to BMI, as shown in Figure 1 (a and b) . Median survival for BMI у28 group was 2.2 years while the reference group had a 65% survival projected at 5 and 9 years. Median EFS for BMI у28 group was 1.4 year while the reference group had a 55% EFS projection at 5 and 9 years. Similar results
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were seen when only the 92 patients treated upfront were considered (Figure 2a and b) . Again, parallel results were observed when the analysis was restricted to the 99 patients who completed the final autograft phase (data not shown). Table 2 summarizes the estimated 1-year and 5-year event-free survival rates according to important prognostic features. On univariate analysis, statistically significant differences in EFS were noted for patients classified for body mass, as well as for IPI score 2-3, histologic subtype and autograft completion. Although EFS was slightly superior among patients treated at diagnosis compared to those treated at relapse, the difference did not reach statistical significance. Other parameters, such as sex, clinical stage, bone marrow involvement did not show any significance in determining disease outcome, according to univariate analyses (data not shown). Using multivariate techniques (Cox proportional hazard model) to adjust for differences in disease characteristics between overweight and patients in the reference group, we observed an independent association between overweight and OS or EFS. As shown in Table 3 , the relative risk for death among overweight patients compared to normal weight patients was 2.9; using EFS as the end-point, the risk for treatment failure was 2.8. The increased risk associated with overweight was similar to that for high IPI score or for inability to complete the final autograft phase.
An analysis was carried out by choosing cut-off values other than 28, ie у26, у24 and у22. These cut-offs failed to identify patient subgroups with statistically significant differences in either OS or EFS.
Discussion
Recently, high-dose chemotherapy and autografting have been widely employed in chemosensitive tumors, especially non-Hodgkin's lymphomas, because of the reduced treatment-related toxicity due to availability of hematopoietic growth factors and mobilized PBPC. [4] [5] [6] [7] [8] [9] [10] [11] The HDS scheme is one of the regimens where these new opportunities have been best exploited. 4 The program is based on drugs given at maximum tolerated doses and it includes a final autograft phase using PBPC previously mobilized and harvested during the high-dose phase. In this study we were interested in verifing if overweight could affect clinical outcome of lymphoma patients homogeneously treated with the original or with the intensified HDS. In other words, the study was designed to investigate the impact of overweight in NHL patients receiving intensive chemotherapy and autografting.
Definition of overweight was based on BMI. This is presently the most common index used to identify overweight. 24 Overweight was defined by BMI у28, as commonly assumed in studies carried out on the general population. 23, 24 In our study group, approximately 30% of the patients had a BMI у28. Less than 8% of the patients considered were massively obese, with a BMI у32. The proportion of overweight and massive obesity found in our patients parallels the distribution in the healthy population. Hence, our sample reflects a general, more than a particular condition.
Globally, patients with BMI у28 had a worse outcome than did those in the reference group, in terms of both OS and EFS. This difference was observed in all the patients enrolled in the study, as well as in only patients who were able to complete the whole program and receive an autograft. Recently, two independent studies have demonstrated that overweight is an adverse prognostic factor in patients with chronic myeloid leukemia or other hematologic malignancies undergoing allogeneic transplantation. 20 , 21 The present study shows for the first time that overweight also has an adverse impact in intensive chemotherapy programs with autografting, at least in high-risk lymphoma patients. Hence, we feel that every overweight patient enrolled in an intensive chemotherapy program with autografting should be clearly informed about the fact that they might have less chances of success.
HDS programs were overall well tolerated with low and acceptable toxicity. We reported five treatment-related fatal events, giving a 4% treatment-related mortality. On subgroup analysis, we could not document reduced tolerance in overweight patients compared to controls. On the contrary, patients with an elevated BMI tolerated the treatment slightly better, with less transfusion requirement and lower incidence and duration of fever episodes following highdose cytotoxic drug administration. Hence, the different outcome cannot be attributed to reduced tolerance in overweight patients. The drug dose delivered was calculated on actual body weight in patients in the reference group, as well as in most of the overweight patients. Only a few massively obese patients had a drug-dose reduction based on their pharmacologic weight. It is reasonable to think that, even receiving comparable doses, final tissue drug concentrations could have been lower in patients with a BMI у28. This is supported by the observation that in spite of no statistically significant difference in hematologic toxicity between the two groups considered, overweight patients tolerated the Bone Marrow Transplantation treatment slightly better than did those in the reference group. Indeed, the HDS approach with autografting as well as other high-dose programs, is based on drugs given at their maximum tolerated dose. This strategy is thought to give maximum tumor cytoreduction, by eliminating both chemosensitive and resistant cells. 29 It is possible that even a very small reduction in the amount of drugs reaching the tumor cells could have a negative impact on treatment efficacy. On the other hand, it is not possible to employ higher doses in overweight patients, due to the potential risks of extrahematologic organ toxicity.
Even a slight reduction of drug delivery to neoplastic tissues is hence the most simple explanation for the worse clinical outcome in overweight patients. However other explanations are possible. A worse outcome has been observed not only in hematology patients undergoing allogeneic transplantation, but also in patients with breast cancer treated conventionally. [18] [19] [20] [21] It cannot be excluded that more general mechanisms are implicated in the worse outcome of overweight patients. A challenging hypothesis is based on an inappropriate production of growth-promoting factors in obese patients, such as insulin-like growth factor. 30 High levels of such factors could render tumor cells more aggressive and hence less sensitive to chemotherapy, in spite of intensive regimens with intensification and autografting.
An analysis carried out on a sufficiently high number of patients with NHL homogeneously treated with a high-dose program enabled us to evaluate other factors with a possible prognostic role in NHL. Several parameters, including sex, age Ͻ or у45 years, bone marrow invasion, disease status at onset or at relapse, were not found to be significant. This last observation was unexpected. However, it has to be considered that relapsed patients were few in number, and some had low-grade lymphoma, so it is possible that the approach at relapse could seem as effective as that seen in patients treated at disease onset. Among the most significant factors, we found a 2-3 age-adjusted IPI score. Thus, an intermediate/high IPI score has an adverse prognostic role not only in conventionally treated patients, but also in NHL patients receiving intensive programs with autografting, as already reported in a group of relapsed patients. 31 Finally, in spite of the small number of cases, the mantle cell subtype turned out to have a significantly worse prognosis compared to the other two groups with low-grade or high-grade histology. This confirms that mantle cell lymphoma is one of the most difficult entities to treat, where even a high-dose approach can offer little if any chance of cure. 32 In conclusion, caution should be exercised when enrolling overweight lymphoma patients in an intensive program with autografting. Multivariate analysis has shown that this parameter could have independent prognostic significance, and is linked to a higher risk of treatment failure. Further studies on patients receiving conventional treatment will verify if the adverse impact of overweight is always true in lymphoma, or if it only applies to intensive programs with autografting.
